Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study

被引：1

作者：

Montillo, Marco ^{[1
]}

Tedeschi, Alessandra ^{[1
]}

Ricci, Francesca ^{[1
]}

Zaccaria, Alfonso ^{[2
]}

Crugnola, Monica ^{[3
]}

Spriano, Mauro ^{[4
]}

Spedini, PierAngelo ^{[5
]}

Ilariucci, Fiorella ^{[6
]}

Uziel, Lilj ^{[7
]}

Attolico, Immacolata ^{[8
]}

De Blasio, Angelo ^{[9
]}

Vismara, Eleonora ^{[1
]}

Morra, Enrica ^{[1
]}

Petrizzi, Valeria Belsito ^{[10
]}

机构：

[1] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy

[2] Santa Maria delle Croci Hosp, Dept Hematol, Ravenna, Italy

[3] Univ Parma, Dept Internal Med & Biol Sci, Hematol & BMT Unit, I-43100 Parma, Italy

[4] San Martino Hosp, Dept Hematol, Genoa, Italy

[5] Hosp Cremona, Div Haematol, Cremona, Italy

[6] Santa Maria Nuova Hosp, Hematol Unit, Reggio Emilia, Italy

[7] San Paolo Univ Hosp, Oncul Unit, Milan, Italy

[8] San Carlo Hosp, Dept Hematol, Potenza, Italy

[9] Santa Maria Goretti Hosp, Hematol Unit, Latina, Italy

[10] Gen Hosp, Oncol & Hematol Unit, Nocera Inferiore, Italy

来源：

关键词：

D O I：

10.1182/blood.V116.21.1384.1384

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：595 / 596

页数：2